Abstract
Overactive bladder has significant impact on a patient’s quality of life. Conservative and pharmacologic management are effective in most patients. Whereas treatment options were limited many years ago for patients who failed first-line therapy, there are now multiple minimally invasive options for them. Detrusor injection of botulinum toxin, which is not yet officially approved for the treatment of idiopathic overactive bladder, significantly improves patient’s symptoms and quality of life, and is well tolerated. Two types of neuromodulation are also available: posterior tibial nerve stimulation and sacral nerve stimulation. Promising new medications are in the pipeline. For those who do not respond to the minimally invasive options, augmentation cystoplasty or urinary diversion remain options.
Financial & competing interests disclosure
HB Goldman is a consultant and speaker for Allergan and Medtronic and he is a speaker for Astellas. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.